Market Overview

UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, Catalysts

Share:
Related ACOR
Acorda Therapeutics 8-K Filing Shows Company WIll Oppose Requests To Institute For IPRS, Will Oppose Full Proceedings And Defend Patents
Benzinga's Top #PreMarket Gainers
Biogen Wins Round In Patent Fight Vs. Kyle Bass (Investor's Business Daily)

Citigroup raised its rating on Acorda Therapeutics (NASDAQ: ACOR) from Neutral to Buy and raised its price target from $28 to $33.

Citigroup said, "We expect Ampyra to continue to grow fueled by modest market share gains and price increases. We project a 10% price increase in Q1:13 and 5% annually thereafter as there is still pricing power for the brand. This is overlooked by investors and should drive Ampyra's growth. We see limited downside to the stock as the stock is undervalued based on DCF esp. after its poor performance in 2012."

Acorda Therapeutics closed at $24.86 on Wednesday.

Latest Ratings for ACOR

DateFirmActionFromTo
Jun 2015Guggenheim SecuritiesInitiates Coverage onNeutral
Apr 2015Piper JaffrayAssumesNeutral
Feb 2015CitigroupMaintainsNeutral

View More Analyst Ratings for ACOR
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ACOR)

Get Benzinga's Newsletters